NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Genitourinary and Pharyngeal Pharmacokinetics of Solithromycin

Phase 1

Completed

Conditions: Gonorrhoea

Interventions: Drug: Solithromycin

First Posted Date: 2015-01-28

Last Posted Date: 2019-01-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 28

Registration Number: NCT02348424

Locations: 🇺🇸
Johns Hopkins Bayview Medical Center - Infectious Diseases, Baltimore, Maryland, United States

Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)

Phase 2

Completed

Conditions: Ebola Virus

Interventions: Biological: Placebo
Biological: ChAd3-EBO Z
Biological: VSVG-ZEBOV

First Posted Date: 2015-01-26

Last Posted Date: 2021-04-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1500

Registration Number: NCT02344407

Locations: 🇱🇷
Liberian Ministry of Health and Social Welfare, Monrovia, Liberia

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Phase 3

Completed

Conditions: HIV
Cardiovascular Diseases

Interventions: Drug: Pitavastatin
Drug: Placebo

First Posted Date: 2015-01-22

Last Posted Date: 2024-10-18

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 7769

Registration Number: NCT02344290

Locations: 🇺🇸
Alabama CRS*, Birmingham, Alabama, United States
🇺🇸
University of Southern California CRS*, Los Angeles, California, United States
🇺🇸
UCLA CARE Center CRS*, Los Angeles, California, United States

and more 134 locations

Collection of Plasma From People Who Recovered From or Were Vaccinated to Emerging Infectious Diseases

Completed

Conditions: Emerging Infectious Diseases
Infection
Communicable Diseases
Communicable Diseases, Emerging

Interventions: Drug: Plasma

First Posted Date: 2015-01-15

Last Posted Date: 2025-05-16

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 10

Registration Number: NCT02338986

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Phase 1 Trial of Inactivated West Nile Virus Vaccine

Phase 1

Completed

Conditions: West Nile Viral Infection

Interventions: Biological: HydroVax-001
Other: Placebo

First Posted Date: 2015-01-14

Last Posted Date: 2019-01-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 96

Registration Number: NCT02337868

Locations: 🇺🇸
Duke Human Vaccine Institute - Duke Clinical Vaccine Unit, Durham, North Carolina, United States

A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults

Phase 1

Completed

Conditions: Schistosomiasis

Interventions: Biological: Sm-TSP-2/Alhydrogel/GLA-AF
Biological: Sm-TSP-2/Alhydrogel
Other: Placebo

First Posted Date: 2015-01-14

Last Posted Date: 2017-06-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 72

Registration Number: NCT02337855

Locations: 🇺🇸
Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States

Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1)

Phase 1

Withdrawn

Conditions: Gastroenteritis Norovirus

Interventions: Biological: Norovirus GII.4 Challenge Pool CIN-1
Other: Placebo

First Posted Date: 2015-01-14

Last Posted Date: 2016-06-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT02337842

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States

Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali

Phase 1

Completed

Conditions: Malaria

Interventions: Biological: Pfs25M-EPA/Alhydrogel
Biological: Pfs230D1M-EPA/Alhydrogel
Drug: TWINRIX
Drug: Menactra

First Posted Date: 2015-01-08

Last Posted Date: 2019-04-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 538

Registration Number: NCT02334462

Locations: 🇲🇱
Malaria Research and Training Center, Bamako, Mali
🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in Thailand

Phase 2

Completed

Conditions: Dengue

Interventions: Biological: TV003
Biological: Placebo for TV003

First Posted Date: 2015-01-07

Last Posted Date: 2018-12-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 266

Registration Number: NCT02332733

Locations: 🇹🇭
Phramongkutklao Hospital, Bangkok, Thailand

Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis

Completed

Conditions: Secondary Progressive Multiple Sclerosis

Interventions: Procedure: Blood Draw
Procedure: CSF collection by lumbar puncture (Optional)

First Posted Date: 2015-01-05

Last Posted Date: 2020-11-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 36

Registration Number: NCT02330965

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
Minneapolis Clinic of Neurology, Golden Valley, Minnesota, United States
🇺🇸
Carolinas Medical Center (CMC), Charlotte, North Carolina, United States

and more 10 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy